ewrobbins.com

User Tools

Site Tools

You are here: start » jc
jc

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
jc [2024/07/04 12:03] – adminjc [2024/11/16 21:11] (current) – admin
Line 7: Line 7:
       * **Finding:** VL had better first-pass success than DL       * **Finding:** VL had better first-pass success than DL
   * CARDS   * CARDS
 +    * [[https://doi.org/10.1016/j.resuscitation.2024.110360 | IV vs IO for OHCA]]
 +      * Finding: IV assoc with better survival and neuro fav outcomes
     * [[https://doi.org/10.1056/NEJMoa2307983 | MINT: Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia]]     * [[https://doi.org/10.1056/NEJMoa2307983 | MINT: Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia]]
       * **Finding**: In patients with acute myocardial infarction and anemia, a liberal transfusion strategy did not significantly reduce the risk of recurrent myocardial infarction or death at 30 days.       * **Finding**: In patients with acute myocardial infarction and anemia, a liberal transfusion strategy did not significantly reduce the risk of recurrent myocardial infarction or death at 30 days.
Line 12: Line 14:
     * [[https://doi.org/10.1056/NEJMoa2404245 | Pantoprazole for MV GI bleed ppx]]     * [[https://doi.org/10.1056/NEJMoa2404245 | Pantoprazole for MV GI bleed ppx]]
       * **Finding**: reduces GIB, no mortality benefit       * **Finding**: reduces GIB, no mortality benefit
 +      * [[https://doi.org/10.1097/CCM.0000000000006376 | Calcium for hyperK]]
 +      * **Finding**: not via membrane stabilization
   * MCS   * MCS
     * [[https://doi.org/10.1056/NEJMoa2312572 | DANGER-SHOCK]]     * [[https://doi.org/10.1056/NEJMoa2312572 | DANGER-SHOCK]]
       * **Finding**: Impella CP reduces mortality       * **Finding**: Impella CP reduces mortality
       * **Significance**: First trial to show mortality benefit from MCS       * **Significance**: First trial to show mortality benefit from MCS
 +  * PULM
 +    * [[ https://www.nejm.org/doi/full/10.1056/NEJMoa2406673 | Depemokimab]]
 +    * [[https://www.nejm.org/doi/full/10.1056/NEJMoa2409712 | Inebilizumab for Treatment of IgG4-Related Disease]]
   * GI   * GI
     * [[https://doi.org/10.1097/HEP.0000000000000817 | Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis]]     * [[https://doi.org/10.1097/HEP.0000000000000817 | Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis]]
jc.1720094608.txt.gz · Last modified: 2024/07/04 12:03 by admin

Page Tools

Except where otherwise noted, content on this wiki is licensed under the following license: CC Attribution-Share Alike 4.0 International
CC Attribution-Share Alike 4.0 International Donate Powered by PHP Valid HTML5 Valid CSS Driven by DokuWiki